Does SAVR or TAVI reduce mortality in older adults with symptomatic severe calcific aortic stenosis?
SAVR and TAVI are life-saving interventions for symptomatic severe calcific aortic stenosis, reducing mortality to match age-matched controls.
Calcific AS is a common chronic progressive condition among older adults and is diagnosed via echocardiography. Symptomatic patients with severe AS have a mortality rate of up to 50% after 1 year, but treatment with SAVR or TAVI reduces mortality to that of age-matched control patients. The type and timing of valve replacement should be built on evidence-based guidelines, shared decision-making, and involvement of a multidisciplinary heart valve team.
Otto et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: